Sale!

CNBP Gene Myotonic Dystrophy Type 2 Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The CNBP Gene Myotonic Dystrophy Type 2 Genetic Test is a specialized diagnostic tool available at DNA Labs UAE, designed to identify mutations in the CNBP gene, which are responsible for causing Myotonic Dystrophy Type 2 (DM2). DM2 is a form of muscular dystrophy that affects muscle function and can lead to a range of symptoms from myotonia, muscle weakness, cataracts, to heart problems. This genetic test is crucial for individuals with a family history of DM2 or those exhibiting symptoms, as it provides definitive diagnosis, allowing for appropriate management and treatment plans to be established. The test is priced at 4400 AED and involves a detailed analysis of the patient’s DNA to detect the specific genetic mutation associated with the condition. Conducted in the state-of-the-art facilities of DNA Labs UAE, this test represents a significant step forward in the personalized care and management of patients with Myotonic Dystrophy Type 2.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

CNBP Gene Myotonic Dystrophy Type 2 Genetic Test

At DNA Labs UAE, we offer the CNBP Gene Myotonic Dystrophy Type 2 Genetic Test for individuals who suspect they may have this genetic disorder. This test can provide valuable information about the presence and severity of myotonic dystrophy type 2, helping patients and their healthcare providers make informed decisions about treatment and management.

Test Components and Price

The CNBP Gene Myotonic Dystrophy Type 2 Genetic Test is priced at 4400.0 AED. The test requires a blood sample, extracted DNA, or one drop of blood on an FTA card.

Report Delivery

Once the sample is received, the report will be delivered within 3 to 4 weeks.

Testing Method

The CNBP Gene Myotonic Dystrophy Type 2 Genetic Test utilizes Next-Generation Sequencing (NGS) technology. NGS allows for the simultaneous analysis of multiple genes, providing a more comprehensive analysis of the CNBP gene compared to traditional methods like Sanger sequencing.

Test Type and Doctor

The CNBP Gene Myotonic Dystrophy Type 2 Genetic Test falls under the category of Neurological Disorders. The test is conducted by a Neurologist in our Genetics department.

Pre-Test Information

Prior to the test, it is essential to provide the clinical history of the patient who is undergoing the CNBP Gene Myotonic Dystrophy Type 2 NGS Genetic DNA Test. Additionally, a genetic counseling session will be conducted to draw a pedigree chart of family members affected by CNBP Gene Myotonic Dystrophy Type 2.

Test Details

The CNBP gene codes for the protein CCHC-type zinc finger nucleic acid binding protein. Myotonic dystrophy type 2 (DM2) is a genetic disorder caused by an expansion of the CCTG repeat in the CNBP gene.

NGS genetic testing is a highly advanced method that can detect and analyze the CCTG repeat expansion in the CNBP gene, providing a comprehensive analysis of the gene. This type of testing can also identify other genetic variants or mutations associated with the development or progression of myotonic dystrophy type 2.

During the test, a DNA sample is obtained from a blood sample or cheek swab. The DNA is then sequenced using NGS technology, and the resulting data is analyzed to identify any abnormalities or variations in the CNBP gene.

The results of the NGS genetic test are crucial for confirming a diagnosis of myotonic dystrophy type 2 and providing information about the size of the CCTG repeat expansion in the CNBP gene. This information is vital for genetic counseling and guiding treatment and management decisions for individuals with myotonic dystrophy type 2.

Choose DNA Labs UAE for accurate and reliable CNBP Gene Myotonic Dystrophy Type 2 Genetic Testing. Our team of experts is committed to providing comprehensive genetic testing services to help individuals and their healthcare providers make informed decisions about their health.

Test Name CNBP Gene Myotonic dystrophy type 2 Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card o
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Neurological Disorders
Doctor Neurologist
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for CNBP Gene Myotonic dystrophy type 2 NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with CNBP Gene Myotonic dystrophy type 2
Test Details

The CNBP gene is a gene that codes for the protein CCHC-type zinc finger nucleic acid binding protein. Myotonic dystrophy type 2 (DM2) is a genetic disorder that is caused by an expansion of the CCTG repeat in the CNBP gene.

NGS (Next-Generation Sequencing) genetic testing is a type of genetic testing that uses high-throughput sequencing technologies to analyze multiple genes simultaneously. In the context of myotonic dystrophy type 2, NGS genetic testing can be used to detect and analyze the CCTG repeat expansion in the CNBP gene.

This type of genetic testing can provide a more comprehensive analysis of the CNBP gene compared to traditional methods, such as Sanger sequencing. It can also potentially detect other genetic variants or mutations that may be associated with the development or progression of myotonic dystrophy type 2.

NGS genetic testing for myotonic dystrophy type 2 can be performed using a sample of DNA, typically obtained from a blood sample or cheek swab. The DNA is sequenced using NGS technology, and the resulting data is analyzed to identify any abnormalities or variations in the CNBP gene.

The results of the NGS genetic test can help confirm a diagnosis of myotonic dystrophy type 2 and provide information about the size of the CCTG repeat expansion in the CNBP gene. This information can be important for genetic counseling, as well as for guiding treatment and management decisions for individuals with myotonic dystrophy type 2.